Mitchell Warren News
-
The largest and most advanced study under way of a vaccine to prevent HIV infection was stopped by U.S. government researchers after an interim look at the data showed it was unlikely to help recipients.
-
Johnson & Johnson struck the first deal to license an experimental AIDS drug before regulatory approval, reigniting debate over how much companies should do to speed access to HIV treatments in poor countries.
-
The Obama administration boosted its pledge to the Global Fund to Fight AIDS, Tuberculosis & Malaria by 38 percent, to $4 billion, while urging changes to make the organization more efficient and more accountable.
-
Drugs made by Gilead Sciences Inc. that can prevent healthy adults from getting HIV didn’t reduce infections in African women because of lack of adherence to treatment, raising questions about the medicines’ usefulness in stopping the spread of AIDS.
-
The White House is poised to release the country’s first comprehensive domestic strategy against AIDS, as funds to prevent infections have failed to halt the epidemic in those most at risk of the disease, AIDS groups said.
-
A daily pill helped protect gay and bisexual men from catching HIV in a study , the first to show that a drug used to treat the world’s deadliest virus can also be used to prevent it.
-
Deaths from AIDS continued to decline last year as the number of people on HIV drugs worldwide surged 21 percent from 2010, according to a report that found poor and middle income countries spent more on treatment.
-
A vaginal gel containing Gilead Sciences Inc. ’s AIDS drug Viread cut HIV infections by as much as 54 percent in a trial in South Africa, the first time such a product has protected women after six previous gels failed.
-
Healthy people can protect themselves from the deadly HIV virus if they take Gilead Sciences Inc.’s Truvada every day. Whether patients will is an issue dividing AIDS advocates as U.S. regulators weigh approving the pill as the first preventative measure against the disease.
-
Gilead Sciences Inc.’s anti-AIDS pill Truvada safely and effectively reduces the risk of HIV for healthy people having sexual intercourse, according to the first U.S. Centers for Disease Control and Prevention guidelines on using the drugs for prevention in heterosexuals.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page